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Cowden disease, also known as multiple hamartoma 
syndrome, is an autosomal dominant cancer 
syndrome with a high risk of breast and thyroid cancer. 
The gene involved has been localized to chromosome 
10q22-23. Recently, the tumour suppressor gene 
PTEN/MMAC1, encoding a putative protein tyrosine or 
dual-specificity phosphatase, was cloned from that 
region and three mutations were detected in patients 
with Cowden disease. We confirmed that the 
PTEN/MMAC1 gene is indeed the gene for Cowden 
disease by a refined localization of the gene to the 
interval between D10S1761 and D10S5415 which 
contains the PTEN/MMAC1 gene and by mutation 
analysis in eight unrelated familial and 11 sporadic 
patients with Cowden disease. Eight different 
mutations were detected in various regions of the 
PTEN/MMAC1 gene. One mutation was detected twice. 
All detected changes in the gene can be predicted to 
have a very deleterious effect on the putative protein. 
Five of the nine patients have a mutation in exon 5 
coding for the putative active site and flanking amino 
acids. Evaluation of the clinical data of the patients in 
which a mutation could be detected gives no clear 
indications for a correlation between the genotype and 
phenotype. In 10 patients no mutation could be 
detected so far. In support of the linkage data, no 
evidence has emerged from the phenotype of these
patients suggestive for genetic heterogeneity. 
INTRODUCTION
Cowden disease (CD) (MIM 158350), also known as multiple 
hamartoma syndrome, is a rare familial cancer disease named after 
the first patient described in 1963 (1). The disease is inherited in 
an autosomal dominant pattem. Characteristic for CD are oral and 
facial papules together with hamartomatous features of the thyroid, 
breast and digestive tract (1,2). Multiple trichilemmomas are 
considered to be the pathological hallmark of the disease (3). CD 
patients have a predisposition to develop both benign and 
malignant neoplasms. Female patients have a high risk of 
developing fibrocystic disease and carcinomas of the breast; also 
goiter, adenomas and follicular cell carcinomas of the thyroid gland 
and polyps of the digestive tract are pail of the disease (4-7).
Apart from the CD manifestations described above a variety of 
neurological symptoms can be found. Lhermitte-Duclos disease 
(LDD), or dysplastic gangiiocytoma of the cerebellum is, together 
with megalencephaly, the most important central nervous system 
manifestation (8), Other neurological signs range from tremor and 
ataxia to epilepsy and mental retardation (8—10, reviewed in 11).
Recently, in an extensive linkage study in 12 CD families, we 
localized the gene for CD to 10q22—23 between the markers 
D10S2J5 and D10S564 (12), There were no indications for 
genetic heterogeneity. The recently cloned tumour suppressor 
gene PTEN/MMACl, encoding a putative tyrosine or dual­
specificity phosphatase (13,14), was suggested to be involved in 
CD (15). We confirmed that the gene is involved in CD by 
refinement of the linkage data and mutation analysis in the 
PTENIMMAC1 gene in eight familial and 11 sporadic CD 
patients. We identified eight different mutations in nine patients.
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Table 1, Summary of the clinical data of the patients and description of the mutations
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Patient Sex Age Skin Thyroid Breast Intestine Urogenital LDD Other neurological 
signs
Head Mutation and predicted 
effect
n331 f 43 goitre carcinoma in situ 
benign lesions
polyps ovarian cysts
uterine
fibromas
4- nm Insertion of TTAC ( exon 
2, nucleotide 1192/1 tl)3; 
{Yumeshift, aa insertion, 
premature stop in codon 63)
N4(F.) 3 m /2f 30-62 + (5) goilre (3) adenocarcinoma (2) 
benign tumors (2)
n.d. ovarian cysts
uterus
myomatosis
+ tn + (5) mac (2) 
meg (3)
GT to TT (intron 4, splice 
site mutation)
n40 m 57 + goitre n.r. n.d. n.d. + mac CAC to CGC: His 123 Arg 
(exon 5)
nl30 f 42 + adenoma — n.d. —
— mac TGT to CGT : Cys^A rg  
(exon 5)
N2 (F.) 2m I l f 29-65 + (9) goiu-e (7) adeno fi bromas (3) 
adenocarcinomas ( t )
polyps (3) uterus
myomatosis ( 1 )
— + mac (8) 
nm ( 1 )
CGA toTGA : ArgpoStop 
(exon 5)
n264 f 38 + goitre fibrocystic disease 
fibroadenomas
n.d. n.d. - + meg CGA to TGA : Argi.^jStop 
(exon 5)
n275 m 46 + — n.r. polyps n.d. + + mac GAA toTAA : G lui^Siop 
(exon 5)
n342 m 47 + goitre IU\ polyps kidney cysts + mac Insertion of A in codon 
I S3 ( exon 6) frameshift, 
premature stop in codon
m
IÜ69 m 33 + n.r. n.d. n.d. + + mac Deletion of GA in N2í>2 
(exon 7) (frameshift, 
premature stop)
For the families the number of patients with a specific symptom are given between brackets. 1’, female; F, familial; LDD, Lhermitte-Duclos disease; m, male; mac, 
macrocephaly; meg, megalencephaly diagnosed by MRI scanning; n.d., no signs but not examined; nm, normal; n.r., not relevant; +, present; -, absent; Skin abnorma­
lities include trichi lemmom as, lichenoid and verrucous papules on the face, oral mucosal papilomatosis, hyperkeratotic lesion on the distal extremities, and punctate 
keratosis on the palms and. soles. Neurological signs include tremor, clumsiness, incoordination, hearing defects, epilepsy and dizzyness.
RESULTS
Fine mapping
Nineteen CA-repeat markers spanning the 10q22-23 region were 
tested in the families N1-N5 (12) and revealed that the Cowden 
critical region is betweenD10SI761 and DI0S54I (Fig. I). In the 
primary linkage study individual N4-I1-10, determining the 
proximal border of the critical region, was considered to be 
affected (12) although his clinical status was disputed. He was 
known to have hyperkeratotic papules, macrocephaly and mild 
ataxia. Recently, clinical re-examination was carried out by an 
independent clinician leading to the conclusion that he is 
unaffected. Apart from macrocephaly and mild unsteadiness, he 
has two hyperkeratotic papules on his forearm and a naevus 
naevocellularis on his scalp. His skin abnormalities only do not 
fulfil the criteria for diagnosis of CD (12) and macrocephaly in 
itself does not justify the diagnosis of CD. Surgical treatment for 
cervical disc disease and a period of alcohol abuse might explain 
his mild unsteadiness. The haplotype in combination with the 
diagnosis of this individual are in accordance of PTENiMMACl 
being the Cowden gene (Fig. 1).
Mutation analysis of the PTEN/MMACl gene
Mutation analysis of the PTEN/MMACl gene was performed 
using lymphocyte DNA of eight familial and 11 sporadic CD 
patients. The nine described exons of the gene were amplified and 
sequenced, hi two families (N2 and N4) and seven sporadic
patients a heterozygous mutation was detected. The mutations are 
listed in Table 1, We identified missense, nonsense, frameshift and 
splice site mutations.
There are three different mutations in the active site sequence 
motif HCxxGxxRS/T of protein tyrosine phosphatases and dual 
specificity phosphatases (16,17). Two of these mutations are 
missense mutations, His 123Arg and Cysl24Arg, and one is a 
nonsense mutation Argl30Stop, which occurred twice (Fig, 2). All 
three can be predicted to lead to a complete or severe loss of 
phophatase activity (17). By sequencing the A-lane with the 
reversed primer, the Argl30Stop mutation was shown to cosegre­
gate with CD in family N2 (Fig. 3). A second nonsense mutation 
Glul57Stop was detected in the sequences flanking the active site 
mid therefore can be expected to reduce the phosphatase activity.
In family N4 the first nucleotide of intron 4 was changed from 
G into T causing a mutation in the nearly invariant splice site 
sequence GU to UU. This will lead either to exon skipping or to 
insertion of intron 4 into the transcript. The mutation was shown 
to completely cosegregate with CD in the family by sequencing of 
the T-lane.
The three remaining mutations lead to a frameshift and 
premature termination of the protein at codons 63, 189 and 297 
which are the eighth, sixth and 36th codon after the frameshift 
mutation, respectively. Also these mutations can be predicted to be 
very deleterious to the protein.
Mutations were confirmed in independently amplified PCR 
fragments. To exclude common polymorphisms, 50 controls 
were tested in whom none of the mutations were found.
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Figure 1. Refinement ol the localization of the gene tor CD; key recombinations. Black circles indicate the affected haplotype, open circles Uie unaffected haplotype 
and grey circlcs un informativi ty. The Cowden critical region is depicted as a black bar. Markers which were used in the linkage analysis described in (12) are given 
in bold. The location of the PTEN/MMACl gene is marked by an arrow. The haplotypes of two healthy sibs from the CD families N4 and N5 , who both have 
macrocephaly, are depicted on the right.
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Figure 2. Excerpt of the sequence of exon 5 using the radioactively labeled 
reversed primer. The heterozygous transversion of G to A in a patient of family 
N2 is marked by an astorix. The substitution is predicted to cause a premature 
slop of the protein at codon 130.
DISCUSSION
We have refined the localization of the CD gene and performed 
mutation analysis in the PTEN/MMACl gene thereby confirming 
that this gene is causative of CD (15). A mutation was detected 
in nine patients, two of whom are familial (N2 and N4). Five of 
these mutations are in exon 5 in addition to three of four described 
by Liaw et al. (15). This suggests that exon 5 (amino acids
86-165), coding for the active site and flanking amino acids, is a 
‘hotspot’ for mutations in patients with CD. So far, missense 
mutations are only found in the active site. The Argl30Stop 
mutation was detected twice in our patient group and once in a 
glioma (14) and is caused by a mutation in a CG dinucleotide. 
Since these are known to have a relatively high mutation 
frequency, the CG in codon 130 might be prone to become 
mutated. In 10 patients no mutation was found. Three of these 
patients are from families linked to 10q22~23 (12). CD in these 
individuals might be due to a change in the promoter sequences, 
deletion of an entire exon which remains undetected with the 
method used, or a mutation in an intron leading to aberrant 
splicing. In support of the linkage data, no evidence has emerged 
from the phenotype of these 10 patients suggestive for genetic 
heterogeneity.
Since different types of mutations were detected in several 
regions of the gene, we made an attempt to correlate symptoms and 
specific mutations. Skin abnormalities including trichilemmomas 
were detected in patients with all types of mutations but not in 
patient n331 although trichilemmomas are pathognomonic for CD 
(3). Patient n331 testifies to the observation in families with CD 
that the skin abnormalities are not fully penetrant (4), The 
combination of oncological features including LDD justifies in our 
opinion die diagnosis of CD. At the same time it raises the question 
which and how many non-dermatological criteria allow the clinical 
diagnosis. The detection of a mutation in this patient indicates that 
the PTENIMMAC1 gene is a good candidate for familial cancer 
disorders with (a combination of) neoplasms associated with CD, 
for example familial breast cancer and/or thyroid cancer, in the 
absence of skin abnormalities.
Involvement of the thyroid was found in the majority of patients 
with the exception of patient n275 with the Glul57Stop mutation
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Figure 3. Analysis of the segregation of the Argi 30Stop mutation in family N2. 
Sequencing of the A-lane was performed using the radioactively labeled 
reversed primer of exon 5.
and patient n269 with a frameshift mutation in exon 7. Patient D 
described by Liaw and co-workers (L5) also has the Glul57Stop 
mutation and no thyroid symptoms too, suggesting that this is 
specific for this mutation. A larger number of patients is necessary 
to confirm a phenotype-genotype correlation for thyroid 
symptoms in CD.
Breast abnormalities are found only in females with the 
exception of one male patient. So far, all affected females have a 
mutation in the N-terminal half of the protein. Within this group 
of females, there are no indications for specific mutations leading 
to breast involvement. Also for intestinal polyps, urogenital 
involvement and neurological signs, there are no indications for 
phenotype-genotype correlations.
LDD is associated with mutations leading to a premature 
termination of the protein and a splice site mutation but not with 
the detected missense mutations. This is also true for the patients 
described by Liaw et al. (15). We cannot confirm their suggestion 
that LDD is associated with the more N-terminal truncations 
since patient n269 has a frameshift mutation in codon 262. 
However, one could argue that the long stretch of 35 changed 
amino acids between the frameshift and the termination might 
have a more deteriorating effect on the protein in comparison to 
the described Arg233 nonsense mutation which is not associated 
with LDD (15).
The identification of the gene involved in CD makes early, 
presymptomatic diagnosis of the disorder possible not only in the 
familial cases but also in the large fraction of sporadic cases in 
whom diagnosis based on linkage analysis cannot be performed. 
This is of great clinical importance since accurate surveillance for 
the occurrence of neoplasms associated with CD can be offered 
now to the carriers. Our study underlines difficulties in the 
diagnosis of CD based on clinical symptoms since we had two 
sibs from CD families suspected for the disorder because of 
macrocephaly: N4-ÏÏ-10, who has been described in the results 
section, and a 5 year old girl (N5-IV-1, Fig* 1 ) with macrocephaly 
and a haemangioma on her ankle occurring regularly in CD. Both 
individuals did not have the affected haplotype in the interval of 
the PTENIMMACJ gene (Fig. 1) and forN4-II-10 we could show 
the absence of the mutation cosegregating with the disorder in the 
family. The mutation in family N5 has not yet been detected. 
These results indicate that in families, macrocephaly as an early
indication for CD has to be treated with caution. In the Dutch 
families N1-N5, macrocephaly is present in 24 of 25 patients but 
also in five of 12 unaffecteds (E.AJ. Peeters, in preparation).
Mutations in the PTENIMMACJ gene causing CD can give 
some clues as to the function of the gene. The presence of 
megalencephaly, and the occasional hypertrophy of breasts and 
increased size of hands and feet in patients with CD (18,19) 
suggest that haploinsufficiency of the gene leads to disturbance 
of growth restriction in development. Furthermore, as already 
suggested by Liaw et al. (15), inactivation of the second allele 
causes disorganization and proliferation resulting in hamartomas, 
the hallmark of CD. Somatic mutations in other tumour 
suppressor genes or oncogenes could then cause malignant 
transformation. The rare occurrence of glioblastoma multiforme 
in CD patients supports the notion that the appearance of this 
tumour is the result of a cascade of events in which a mutation in 
the PTENIMMAC1 gene probably is the last step. Furthermore, 
the putative nature of the gene i.è. a protein tyrosine or dual 
specificity phosphatase is in agreement with the observed features 
of CD: these phosphatases are involved in cell proliferation and 
cell differentiation (17). The occurrence of acquired mutations in 
the PTENIMMAC1 gene in a number of tumour types (13,14) and 
the germline mutations causing the rare CD makes this gene 
comparable to p53 showing mutations in many tumour types and 
in the rare Li-Fraumeni syndrome, promising interesting future 
results on the PTENIMMAC1 gene.
MATERIALS AND METHODS
Patients
Diagnoses of patients were based on demiatological criteria with 
the exception of patient n331 (see Table I), In this patient 
diagnosis was based on the oncological features and LDD. 
Fine-mapping was performed in the families NI-N5, The 
families N1 and N2 have been described by Starink et al. (4) and 
the families N4 and N5 by Padberg et al. (8). Patient n275 is 
described by Lindboe et a l (20). Clinical features of patients in 
which a mutation was detected are summarized in Table 1.
Typing of CA repeat markers
Genomic DNA used for the typing of the DNA polymorphisms 
was isolated as reported before (21). Amplification and 
separation of the polymorphic CA-repeat fragments were 
performed as described (22). The markers and their order were as 
given by Genethon (23) with the exception of DÌ0SÌ76Ì and 
D10S532 which are ordered according to recombinations in our 
families.
Mutation analysis
For mutation analysis, DNA fragments containing the exons were 
amplified using the inner primers described in ( 14). PCR products 
were purified from the reaction mixtures using QIA quick spin 
colums (Qiagen) according to the gel extraction protocol. The 
fragments were sequenced using the ds cycle-sequencing system 
(Gibco-BRL) following the manufacturer’s protocol.
Analysis of control individuals
The presence of the detected mutations in 50 unrelated and 
unaffected individuals was tested in lymphocyte DNA isolated as
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described (21). For the mutations in the exons 4, 5 and 6, 
oligonucleotides of 14-16 bp were developed with approxi­
mately in the middle either the wildtype or mutated nucleotide. 
Exons were amplified as described and blotted onto geneScreen 
Plus. Ten nanograms of the oligonucleotides were radioactively 
labeled and used for hybridization in 5x SSPE (0,15 M NaCl, 10 
mM NaH2P04, 10 mM EDTA, pH 7.4), 0.3% SDS at 37°C for 
at least 6 h. After hybridization blots were washed in 5x SSPE, 
0.3% SDS for 15 min at room temperature and 2-5 min at 37 °C. 
The insertions in exons 2 and 7 were tested as length 
polymorphisms by amplifying the exons as described and 
separating them as described for the CA repeat markers (22).
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